Scarica l'app Stockscreener
5.25
1.32%
-0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.32
Aprire:
$5.32
Volume 24 ore:
2.22M
Relative Volume:
1.11
Capitalizzazione di mercato:
$1.07B
Reddito:
-
Utile/perdita netta:
$-115.65M
Rapporto P/E:
-9.8113
EPS:
-0.5351
Flusso di cassa netto:
$-99.27M
1 W Prestazione:
-0.38%
1M Prestazione:
-6.25%
6M Prestazione:
+47.47%
1 anno Prestazione:
+90.22%
Intervallo 1D:
$5.12
$5.51
Intervallo di 1 settimana:
$5.12
$5.84
Portata 52W:
$1.89
$7.005
Savara Inc Stock (SVRA) Company Profile
Nome
Savara Inc
Settore
Industria
Telefono
51285113796
Indirizzo
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.25 | 1.07B | 0 | -115.65M | -99.27M | -0.5351 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-11-13 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-11-07 | Iniziato | Guggenheim | Buy |
| 2023-05-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-31 | Downgrade | Jefferies | Buy → Hold |
| 2021-03-16 | Iniziato | Piper Sandler | Overweight |
| 2021-03-15 | Iniziato | Oppenheimer | Outperform |
| 2019-06-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-13 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Ripresa | ROTH Capital | Neutral |
| 2018-01-03 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-09-27 | Ripresa | ROTH Capital | Buy |
| 2017-09-22 | Iniziato | Jefferies | Buy |
| 2017-09-11 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Savara Inc Borsa (SVRA) Ultime notizie
SVRA SEC FilingsSavara Inc 10-K, 10-Q, 8-K Forms - Stock Titan
SVRASavara Inc Latest Stock News & Market Updates - Stock Titan
Savara (NASDAQ:SVRA) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Decoding Savara Inc (SVRA): A Strategic SWOT Insight - GuruFocus
Savara Inc. 2025 Annual Report: MOLBREEVI Clinical Progress, Business Strategy, and Key Risk Factors - Minichart
Savara Says FDA Review of MOLBREEVI to Proceed Without Advisory Committee - MyChesCo
Savara (SVRA) Advances with MOLBREEVI, Boosting Financial Positi - GuruFocus
Savara Signs Long-Term Lease for New Headquarters - TipRanks
Savara (NASDAQ: SVRA) details new Yardley headquarters lease terms - Stock Titan
SVRA: Regulatory progress and robust cash position set the stage for a potential 2026 launch - TradingView
Savara receives FDA priority review for rare lung disease drug - Investing.com
Savara : Corporate Presentation - marketscreener.com
Earnings Flash (SVRA) Savara Posts Q4 Loss $0.13 a Share, vs. FactSet Est of $0.12 Loss - marketscreener.com
Savara Q4 net loss widens as expenses rise - TradingView
Savara 10-K: $0M Revenue, $0.00 EPS; $118.8M Net Loss - TradingView
SVRA: Net loss increased to $118.8M in 2025 as MOLBREEVI advanced toward FDA review and commercialization - TradingView
MOLBREEVI strategy and FDA Priority Review drive Savara (NASDAQ: SVRA) - Stock Titan
BRIEF-Savara Q4 Net Income USD -32.236 Million - TradingView
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - The Joplin Globe
Rosalind Advisors Inc. Has $14.28 Million Position in Savara Inc. $SVRA - MarketBeat
Aug Shorts: Why is Savara Inc stock going down2026 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
How FDA’s No-Advisory-Committee Path for MOLBREEVI Could Shape Savara (SVRA) Investors’ Outlook - simplywall.st
FY2030 Earnings Forecast for Savara Issued By HC Wainwright - MarketBeat
Savara receives FDA day 74 letter for autoimmune PAP drug - Investing.com Nigeria
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - BioSpace
Savara Inc. Announces Equity Awards for New Employees - MSN
Savara receives FDA day 74 letter for autoimmune PAP drug By Investing.com - Investing.com Australia
Savara (SVRA) Advances MOLBREEVI Application with FDA and EMA - GuruFocus
Savara Provides Regulatory Update on the MOLBREEVI* Development P - The National Law Review
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Benzinga
Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVIWhat's Changed - Yahoo Finance
Savara Inc (NASDAQ: SVRA) recently announced that it has received a Day 74 letter from the U.S. Food and Drug Administration (FDA). - Bitget
Savara Inc. Confirms Participation in 2026 Citizens Life Sciences Conference Focused on Rare Respiratory Diseases - geneonline.com
Savara Announces Participation in 2026 Citizens Life Sciences Conference - Business Wire
Savara’s MOLBREEVI BLA Receives FDA Priority Review - MyChesCo
Why Savara (SVRA) Is Up 5.4% After FDA Grants Priority Review To MOLBREEVI Application - simplywall.st
Savara Inc. (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears - MarketBeat
SVRA PE Ratio & Valuation, Is SVRA Overvalued - Intellectia AI
Assessing Savara (SVRA) Valuation After FDA Priority Review For MOLBREEVI - simplywall.st
Savara, Inc. (SVRA) Investor Outlook: An 81% Upside Potential In Rare Respiratory Disease Treatment - DirectorsTalk Interviews
Savara Announces Participation in Upcoming Investor Healthcare Conferences - Business Wire
SVRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Citizens reiterates Savara stock rating on likely FDA approval - Investing.com Nigeria
Is FDA Priority Review for MOLBREEVI Reshaping the Investment Case for Savara (SVRA)? - simplywall.st
Savara Grants Inducement Equity Awards to New Employee - MyChesCo
Citizens reiterates Savara stock rating on likely FDA approval By Investing.com - Investing.com India
FDA accepts Savara’s drug application for rare lung disease By Investing.com - Investing.com Australia
Savara, Inc. (SVRA) Stock Analysis: Biotech Player With An 89% Upside Potential - DirectorsTalk Interviews
Savara (SVRA) Gains Priority Review for Molbreevi by FDA - GuruFocus
FDA accepts Savara’s drug application for rare lung disease - Investing.com India
Savara Inc Azioni (SVRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Savara Inc Azioni (SVRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| RAMSAY DAVID A | Director |
Dec 19 '25 |
Sale |
6.06 |
20,000 |
121,220 |
2,533,642 |
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):